Patient-derived xenograft (PDX) models can maintain the original histology and the molecular and genetic characteristics of the source tumour. Thus, PDX models have advantages over conventional models for drug development and treatment decisions in personalized medicine. In this Review, the authors discuss the potential of PDX models for both basic and clinical urological research.
- Takahiro Inoue
- Naoki Terada
- Osamu Ogawa
